Trials / Completed
CompletedNCT00529581
A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons With Multiple Sclerosis With Cognitive Impairment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Cognition Pharmaceuticals, LLC · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and efficacy of C105 in treating the cognitive deficits that can occur due to multiple sclerosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | C105 |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2008-03-01
- Completion
- 2008-04-01
- First posted
- 2007-09-14
- Last updated
- 2008-05-28
Locations
30 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00529581. Inclusion in this directory is not an endorsement.